https://www.selleckchem.com/btk.html
hich warrants further in-depth investigation.Introduction Bone and soft tissue sarcomas express fibroblast activation protein (FAP) on tumor cells and associated fibroblast. Therefore, FAP is a promising therapeutic and diagnostic target. Novel radio-labelled FAP-Inhibitors (e.g. 68Ga-FAPI46) have shown high tumor uptake in positron emission tomography (PET) in sarcoma patients. Here we report endpoints of the FAPI-PET prospective observational trial. Methods Forty-seven patients with bone or soft tissue sarcomas undergoing clinical 68Ga-FAPI-PET we
Like
Comment
Share
